Exactech Polyethylene Orthopedic

The Exactech Polyethylene Orthopedic litigation, centralized before Judge Nicholas G. Garaufis in the Eastern District of New York in October 2022, consolidates claims that knee, hip, and ankle joint-replacement implants failed prematurely because defective vacuum-sealed packaging allowed oxygen to reach the polyethylene components, accelerating oxidation and degradation once implanted. With 1,838 of 1,847 total actions still pending, this is a docket where almost the entire original filing volume remains active — a fact pattern that tells a funder this litigation is still building toward its defining pretrial milestones rather than winding down toward resolution.

For claim-level and portfolio underwriting alike, the packaging-defect theory here is a double-edged asset: it is mechanically straightforward to explain to a jury and ties cleanly to manufacturing records Exactech itself generated, but individual claim strength still depends heavily on implant-specific facts — which device lot, how long it was in place before failure, and whether revision surgery confirmed the alleged oxidative degradation. A firm building a portfolio of these claims should weight its inventory toward cases with confirmed revision-surgery findings, since those claims carry the clearest causation link between the packaging defect and the injury.

Medical-lien exposure is meaningful in this docket because joint-replacement revision surgery is expensive and often involves extended rehabilitation, meaning insurers and providers will have real claims against any eventual recovery. Because the docket has not yet reached a bellwether or settlement phase, funding structures here should be built for a longer duration horizon than a docket further along in pretrial development, with pricing anchored to individual medical and device records rather than to comparable settlement data that does not yet exist. Criterica Capital's mass tort finance product is the relevant path for claims and portfolios in this litigation, and a structural brief covering the docket in more depth is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.